Abstract Search

Radiolabeled peptides that target with high affinity and specificity their receptors on tumor cells are being applied as nuclear tracers for both diagnostic imaging and targeted radionuclide therapy with great success. It is an extensive process to bring a newly designed radiolabelled peptide molecule from its design into the clinic however and from a vast number of newly designed and developed radiolabeled peptides only few will finally meet the conditions for clinical applic...

0 shares

ea0049ep1445 | Thyroid (non-cancer) | ECE2017

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

Hubalewska-Dydejczyk Alicja , Erba Paola , Decristoforo Clemens , Zaletel Katja , Mikolajczak Renata , Maecke Helmut , Maina-Nock Theodosia , Konijnenberg Mark , Kolenc-Peitl Petra , Trofimiuk-Muldner Malgorzata , Przybylik-Mazurek Elwira , Virgolini Irene , Pawlak Dariusz , de Jong Marion , Froberg Alide C , Rangger Christine , Goebel Georg , Scarpa Lorenza , Skorkiewicz Konrad , Lezaic Luka , Garnuszek Pirotr , Sowa-Staszczak Anna , Nock Berthold A , Bergant Damijan , Rep Sebastijan , Glowa Boguslaw

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...

0 shares

Endocrine Abstracts

Benefits and challenges of translating pre-clinical studies into clinical practice

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

BiosciAbstracts